TY - JOUR
T1 - Health care-associated pneumonia (HCAP)
T2 - A critical appraisal to improve identification, management, and outcomes-proceedings of the HCAP summit
AU - Kollef, Marin H.
AU - Morrow, Lee E.
AU - Baughman, Robert P.
AU - Craven, Donald E.
AU - McGowan, John E.
AU - Micek, Scott T.
AU - Niederman, Michael S.
AU - Ost, David
AU - Paterson, David L.
AU - Segreti, John
N1 - Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Health Care–Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes—Proceedings of the HCAP Summit,” sponsored by Medical Education Resources and Consensus Medical Communications and supported by an unrestricted educational grant from Ortho-McNeil administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Funding Information:
Potential conflicts of interest. M.H.K. has received grants/research support from Merck, Pfizer, Elan, Bard, Wyeth, and Johnson & Johnson. L.E.M. has been a speakers’ bureau participant for Pfizer, Ortho-McNeil, and Schering Plough. D.E.C. has received grants/research support from Bard and Nomir; has been a speakers’ bureau participant for Merck, Elan, Pfizer, Wyeth, and Sanofi Pasteur; and has received financial support from the Data and Safety Monitoring Board of Johnson & Johnson. J.E.M. has received grants/research support from AstraZeneca, Elan, Johnson & Johnson, PRD, Pfizer, and 3M, and has been a consultant for Merck, Elan, Replidyne, and Wyeth. S.T.M. has received grants/research support from Johnson & Johnson. M.S.N. has been a consultant, shareholder, and speakers’ bureau participant for Pfizer, Schering Plough, Ortho-McNeil, Aventis, Merck, Elan, AstraZeneca, and Wyeth. D.L.P. has received grants/research support from AstraZeneca, Elan, and Pfizer; has been a consultant for Merck, Cubist Pharmaceuticals, Elan, Genzyne, KeyBay, Acureon, Wyeth, and Johnson & Johnson; and has been a speakers’ bureau participant for Merck, Elan, and Cubist Pharmaceuticals. All other authors: no conflicts.
PY - 2008/4/15
Y1 - 2008/4/15
N2 - Increasingly, patients are receiving treatment at facilities other than hospitals, including long-term-health care facilities, assisted-living environments, rehabilitation facilities, and dialysis centers. As with hospital environments, nonhospital settings present their own unique risks of pneumonia. Traditionally, pneumonia in these facilities has been categorized as community-acquired pneumonia (CAP). However, the new designation for pneumonias acquired in these settings is health care-associated pneumonia (HCAP), which covers pneumonias acquired in health care environments outside of the traditional hospital setting and excludes hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and CAP. Although HCAP is currently treated with the same protocols as CAP, recent evidence indicates that HCAP differs from CAP with respect to pathogens and prognosis and, in fact, more closely resembles HAP and VAP. The HCAP Summit convened national infectious disease opinion leaders for the purpose of analyzing current literature, clinical trial data, diagnostic considerations, therapeutic options, and treatment guidelines related to HCAP. After an in-depth analysis of these areas, the infectious disease investigators participating in the summit were surveyed with regard to 10 clinical practice statements. The results were then compared with results of the same survey as completed by 744 Infectious Diseases Society of America members. The similarities and differences between those survey results are the basis of this publication.
AB - Increasingly, patients are receiving treatment at facilities other than hospitals, including long-term-health care facilities, assisted-living environments, rehabilitation facilities, and dialysis centers. As with hospital environments, nonhospital settings present their own unique risks of pneumonia. Traditionally, pneumonia in these facilities has been categorized as community-acquired pneumonia (CAP). However, the new designation for pneumonias acquired in these settings is health care-associated pneumonia (HCAP), which covers pneumonias acquired in health care environments outside of the traditional hospital setting and excludes hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and CAP. Although HCAP is currently treated with the same protocols as CAP, recent evidence indicates that HCAP differs from CAP with respect to pathogens and prognosis and, in fact, more closely resembles HAP and VAP. The HCAP Summit convened national infectious disease opinion leaders for the purpose of analyzing current literature, clinical trial data, diagnostic considerations, therapeutic options, and treatment guidelines related to HCAP. After an in-depth analysis of these areas, the infectious disease investigators participating in the summit were surveyed with regard to 10 clinical practice statements. The results were then compared with results of the same survey as completed by 744 Infectious Diseases Society of America members. The similarities and differences between those survey results are the basis of this publication.
UR - http://www.scopus.com/inward/record.url?scp=42549136960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42549136960&partnerID=8YFLogxK
U2 - 10.1086/526355
DO - 10.1086/526355
M3 - Article
C2 - 18429676
AN - SCOPUS:42549136960
SN - 1058-4838
VL - 46
SP - S296-S334
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -